Mertz L, Mathelin C, Marin C, Gairard B, Chenard M P, Brettes J P, Bellocq J P, Constantinesco A
Service de médecine nucléaire, Hôpital de Hautepierre, avenue Molière, 67200 Strasbourg.
Bull Cancer. 1999 Nov;86(11):939-45.
The objective were to study the relevance of the subareolar injection for sentinel node [SN] detection in multiple foci breast cancer. Seventy-nine patients with infiltrative breast carcinoma (diagnosed pre-operatively by core biopsy) and a mean age of 55 (31-78) years were enrolled. All patients were free of previous homolateral surgery, chemotherapy, locoregional radiotherapy or prevalent axillary lymph node. Using four 0.1 ml injections of 1.8 MBq, the technetium-99m 100 nm filtered sulfur colloid was injected by subareolar way (group I) in 16 cases of radiologically cancer with multiple invasive foci and 31 cases of radiologically unifocal cancer, and by peritumoral way (group II) in 32 cases of radiologically unifocal cancer. Scintigrams were obtained 2 to 4 hours after the injections and radioactive nodes were detected peroperatively 18 hours after the injection by intraoperative detection probe. Individual removal of all radioactive nodes was followed by axillary dissection at levels I and II of Berg including Rotter area control. All sentinel nodes were submitted to standard histopathological analysis on serial sections at 500 mu intervals completed by immunohistochemistry for cytokeratin on negative SN. SN were detected by scintigrams in 85% and 88% of the cases of group I and group II respectively, but in 98% and 97% of the cases of respectively both groups by intraoperative probe. Group I was composed of 69% ductal, 22% lobular and 9% tubular carcinomas, and group II of 87% ductal, 10% lobular and 3% tubular carcinomas. Seven and 5 radiologically unifocal tumors were in fact with multiple invasive foci at histology in groups I and II respectively. The complete scintigraphic procedure permitted the detection of a mean number of 2.7 (1-7) SN in group I and 2.3 (1-4) in group II (NS). In group I, the SN were metastatic in 22 patients (48%), 15 of them with the metastases being restricted to the SN, whereas in group II, the SN were metastatic in 9 patients (28%), 5 of them with the positivity restricted to the SN. No false negative result (SN negative and other axillary nodes positive) was observed in group I and only one false negative result in group II which was related to a cancer with histological multiple invasive foci. Sensitivities were 100% and 90%, and negative predictive values were 100% and 95%, for groups I and II respectively. Subareolar injection of radiocolloid allows identification of SN in cases of unifocal and multiple cancer. The mean number of SN detected by the subareolar method is not significantly different, although higher, to that detected by peritumoral injection.
目的是研究乳晕下注射在多灶性乳腺癌前哨淋巴结(SN)检测中的相关性。纳入了79例浸润性乳腺癌患者(术前经粗针活检确诊),平均年龄55岁(31 - 78岁)。所有患者既往均未接受过同侧手术、化疗、局部区域放疗或存在腋窝淋巴结转移。对16例影像学检查发现有多个浸润灶的癌灶及31例影像学检查发现为单灶性癌的患者,采用乳晕下注射法(I组),注射4次0.1 ml的1.8 MBq锝 - 99m 100 nm过滤硫胶体;对32例影像学检查发现为单灶性癌的患者,采用瘤周注射法(II组)。注射后2至4小时获取闪烁扫描图像,注射后18小时通过术中探测探头在手术中检测放射性淋巴结。对所有放射性淋巴结进行单独切除,随后进行Berg I级和II级腋窝清扫,包括Rotter区域控制。所有前哨淋巴结均进行标准组织病理学分析,以500μm间隔进行连续切片,并对阴性前哨淋巴结进行细胞角蛋白免疫组化检查。I组和II组分别有85%和88%的病例通过闪烁扫描图像检测到前哨淋巴结,但两组分别有98%和97%的病例通过术中探头检测到前哨淋巴结。I组由69%的导管癌、22%的小叶癌和9%的管状癌组成,II组由87%的导管癌、10%的小叶癌和3%的管状癌组成。I组和II组分别有7例和5例影像学检查为单灶性的肿瘤在组织学检查时发现有多个浸润灶。完整的闪烁扫描程序在I组检测到的前哨淋巴结平均数量为2.7个(1 - 7个),II组为2.3个(1 - 4个)(无显著性差异)。在I组中,22例患者(48%)的前哨淋巴结有转移,其中15例转移仅局限于前哨淋巴结;而在II组中,9例患者(28%)的前哨淋巴结有转移,其中5例阳性仅局限于前哨淋巴结。I组未观察到假阴性结果(前哨淋巴结阴性而其他腋窝淋巴结阳性),II组仅1例假阴性结果,与1例组织学检查有多个浸润灶的癌症有关。I组和II组的敏感性分别为100%和90%,阴性预测值分别为100%和95%。乳晕下注射放射性胶体可在单灶性和多灶性癌症病例中识别前哨淋巴结。乳晕下注射法检测到的前哨淋巴结平均数量虽高于瘤周注射法,但无显著性差异。